Merck & Company, Inc. Press Releases

MRK 
$55.74
*  
0.57
1.01%
Get MRK Alerts
*Delayed - data as of Apr. 28, 2016  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
3/7/2016 4:30:00 PM - Business Wire
▲7.03 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
3/7/2016 8:00:00 AM - Business Wire
▲7.48 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
3/4/2016 10:00:00 AM - Business Wire
▲7.65 % Price Change since this news event. The Volume Ratio is 0.95.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Second-Quarter 2016 Dividend
2/23/2016 1:30:00 PM - Business Wire
▲9.98 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Puts Spotlight on Women's Health and Well-being
2/22/2016 11:30:00 AM - PR Newswire


Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
2/22/2016 8:00:00 AM - Business Wire
▲10.03 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
2/15/2016 5:30:00 PM - Business Wire
▲13.76 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
2/4/2016 8:00:00 AM - Business Wire
▲11.73 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
2/3/2016 6:45:00 AM - Business Wire
▲13.52 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day